Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

product recall

- PMLiVE

FDA adds blood clot warning to testosterone products

Warns of risk of developing deep vein thrombosis and pulmonary embolism

- PMLiVE

Teva’s chair Philip Frost to step down

He will leave the Israeli pharma company by the end of the year

- PMLiVE

Halozyme to resume pancreatic cancer study

FDA says PEGPH20 trial can continue

- PMLiVE

Teva restructures to stengthen unit identities

First major change at Israeli firm since Erez Vigodman’s appointment as CEO

- PMLiVE

Teva to use cloud-based CRM for sales force

Picks Veeva’s system to streamline operations

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

Publicis recruits Kylie Minogue for French cancer campaign

Australian singer is taking centre stage in a new Alliance for Research in Cancer initiative

- PMLiVE

EMA to carry out four safety reviews

And recommends against combination of medicines affecting RAS system in latest PRAC highlights

France flag

French pharmacists have role in preventative health

Leading academic calls for greater emphasis on pharmacy in health policy

- PMLiVE

Teva launches first generic of GSK’s Lovaza in US

Will have six months of marketing exclusivity for copy of cardiovascular drug

- PMLiVE

US jury says Takeda and Lilly must pay $9bn in Actos damages

Court says companies covered up cancer risks of diabetes drug

- PMLiVE

Halozyme halts pancreatic cancer trial

The biopharma company is investigating PEGPH20’s links to blood clot

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links